Jun 2026 (Q2 FY26) — Aug 6, 2026
Karman Holdings Q2 FY26 — Record Backlog and Strong Organic Growth Drive Raised Outlook
Read the full callKarman Holdings earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 182 | +58.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 19.1 | +1.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 14.0 | +106.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
1Y: $75.03 on 17 Oct 2025 → $33.91. High $115.29 (28 Jan 2026), low $30.14 (14 Oct 2026).
Overview
Call summaries
Karman Holdings Q2 FY26 — Record Backlog and Strong Organic Growth Drive Raised Outlook
Read the full callKarman Q1 FY26 — Record Performance and Raised Full-Year Guidance
Read the full callKarman Holdings Q4 FY25 — Record Performance and Strong Demand Outlook
Read the full callEvery analysed call
Financials
Net profit, year on year: +106% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 86 | 91 | 100 | 115 | 122 | 134 | 151 | 182 |
| Operating profit | 17 | 14 | 10 | 20 | 22 | 21 | 21 | 35 |
| Operating margin | 20.3% | 15.8% | 9.9% | 17.5% | 17.9% | 15.7% | 14.2% | 19.1% |
| Interest | 13 | 13 | 11 | 12 | 10 | 11 | 13 | 15 |
| Profit before tax | 5 | 2 | -1 | 9 | 12 | 14 | 9 | 19 |
| Tax rate | 17.9% | 15.0% | −222.0% | 20.8% | 35.5% | 43.1% | 9.7% | 27.2% |
| Net profit | 4 | 2 | -5 | 7 | 8 | 8 | 8 | 14 |
| EPS ($ per share) | 0.03 | — | -0.04 | 0.05 | 0.06 | — | 0.06 | 0.11 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Equity capital | — | — | 0 | 0 |
| Reserves | — | — | -8 | 9 |
| Total liabilities | — | 528 | 578 | 721 |
| Fixed assets | — | 52 | 61 | 95 |
| Total assets | — | 711 | 774 | 1,104 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | -6 | 20 | 27 | -22 |
| Cash from investing | -21 | -16 | -46 | -238 |
| Cash from financing | 17 | -5 | 26 | 283 |
| Net cash flow | -10 | -1 | 6 | 22 |
| Capital expenditure | -21 | -17 | -15 | -20 |
| Free cash flow | -27 | 4 | 11 | -42 |
| Segment | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|
| Tactical Missile and Integrated Defense Systems | — | — | — | 38% | 30% | 35% | — |
| Hypersonic and Strategic Missile Defense | — | — | — | 36% | 24% | 24% | — |
| Space and Launch | — | — | — | — | 29% | 23% | — |
| Maritime Defense Systems | — | — | — | — | 17% | 18% | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Backlog | $801MAdjusted EBITDA of $42 million, another quarterly record for Karman, and backlog reached an all-time high of $801 million.Source: earnings call transcript | $1B+Record quarterly gross profit of $64 million, record quarterly adjusted EBITDA of $45 million, all-time high backlog of more than $1 billion.Source: earnings call transcript | $1.3BRecord backlog of $1.3 billion, record quarterly bookings of nearly $500 million, initial fit-up of a 200,000 square foot factory in Salt Lake City with production capability online before the end of 2026.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
24 filings between Nov 12, 2025 and Sep 16, 2026.
Purchases
$1.04M
3 purchases by 3 insiders
Sales
$41.17M
8 sales by 5 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Koblinski Anthony | — | $19.63M | Dec 12, 2025 |
| Willis Michael | — | $6.74M | Nov 17, 2025 |
| Raduenz Brian | — | $6.12M | Nov 12, 2025 |
| Beaudoin Jonathan | — | $4.71M | Nov 13, 2025 |
| Sawhill Stephanie | — | $3.96M | Nov 13, 2025 |
| Stinnett David | $1.01M | — | Sep 16, 2026 |
| Petryszyn Mary D | $18.7K | — | Sep 16, 2026 |
| Twitty Stephen | $10.1K | — | Sep 16, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 16, 2026 | Stinnett David Director | Purchase | 27,000 | $1.01M |
| Sep 16, 2026 | Petryszyn Mary D Director | Purchase | 500 | $18.7K |
| Sep 16, 2026 | Twitty Stephen Director | Purchase | 275 | $10.1K |
| Sep 14, 2026 | Boynton Chris Michael CHIEF FINANCIAL OFFICER | Award | 11,358 | $0 |
| May 21, 2026 | Petryszyn Mary D Director | Award | 2,363 | $0 |
| May 21, 2026 | Beaudoin Jonathan Chief Operating Officer | Award | 689 | $0 |
| May 21, 2026 | Hamilton John Director | Award | 1,962 | $0 |
| May 21, 2026 | RAMBEAU JON Chief Executive Officer | Award | 99,937 | $0 |
| May 21, 2026 | Stinnett David Director | Award | 1,962 | $0 |
| May 21, 2026 | Twitty Stephen Director | Award | 2,363 | $0 |
| May 21, 2026 | Willis Michael Chief Financial Officer | Award | 689 | $0 |
| May 21, 2026 | Sawhill Stephanie Former Chief Growth Officer | Award | 689 | $0 |
| May 21, 2026 | Alty Matthew Director | Award | 2,363 | $0 |
| May 21, 2026 | Koblinski Anthony Director | Award | 1,149 | $0 |
| May 21, 2026 | Laurendeau Doug Chief Growth Officer | Award | 10,864 | $0 |
| May 21, 2026 | Raduenz Brian Director | Award | 2,363 | $0 |
| Dec 12, 2025 | Koblinski Anthony Chief Executive Officer | Sale 10b5-1 plan | 75,000 | $5.20M |
| Dec 5, 2025 | Koblinski Anthony Chief Executive Officer | Sale 10b5-1 plan | 75,000 | $4.99M |
| Nov 28, 2025 | Koblinski Anthony Chief Executive Officer | Sale 10b5-1 plan | 75,000 | $5.05M |
| Nov 21, 2025 | Koblinski Anthony Chief Executive Officer | Sale 10b5-1 plan | 75,000 | $4.39M |
| Nov 17, 2025 | Willis Michael Chief Financial Officer | Sale 10b5-1 plan | 115,000 | $6.74M |
| Nov 13, 2025 | Beaudoin Jonathan Chief Operating Officer | Sale 10b5-1 plan | 74,000 | $4.71M |
| Nov 13, 2025 | Sawhill Stephanie Chief Growth Officer | Sale 10b5-1 plan | 62,000 | $3.96M |
| Nov 12, 2025 | Raduenz Brian Director | Sale 10b5-1 plan | 90,000 | $6.12M |
| Jul 25, 2025 | Hamilton John Director | Other | 54,796 | $0 |
| Jul 25, 2025 | Raduenz Brian Director | Sale | 34,032 | $1.67M |
| Jul 25, 2025 | Stinnett David Director | Other | 3,501,433 | $0 |
| Jul 25, 2025 | TCFIII Spaceco SPV LP 10% owner | Sale | 23,623,968 | $1.16B |
| Jul 25, 2025 | TCFIII Spaceco SPV LP 10% owner | Other | 50,450,859 | $0 |
| Jul 25, 2025 | Willis Michael Chief Financial Officer | Sale | 100,000 | $4.90M |
| Jul 25, 2025 | Koblinski Anthony Chief Executive Officer | Sale | 250,000 | $12.25M |
| Jul 25, 2025 | Beaudoin Jonathan Chief Operating Officer | Sale | 80,000 | $3.92M |
| Jul 25, 2025 | Sawhill Stephanie Chief Growth Officer | Sale | 62,000 | $3.04M |
| Feb 14, 2025 | Willis Michael Chief Financial Officer | Sale | 72,727 | $1.60M |
| Feb 14, 2025 | Sawhill Stephanie Chief Growth Officer | Sale | 72,727 | $1.60M |
| Feb 14, 2025 | Koblinski Anthony Chief Executive Officer | Sale | 379,055 | $8.34M |
| Feb 14, 2025 | Koblinski Anthony Chief Executive Officer | Sale | 2,764 | $60.8K |
| Feb 14, 2025 | Beaudoin Jonathan Chief Operating Officer | Sale | 72,727 | $1.60M |
| Feb 14, 2025 | TCFIII Spaceco SPV LP Director | Sale | 9,686,678 | $213.11M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Karman Holdings Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading